Chronic Allograft Dysfunction - Is There a Treatment?

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Background. The major causes of renal transplant loss are death and chronic allograft dysfunction (CAD). The aims of this study were to determine the incidence of CAD in our population and the relation between allograft survival and immunosuppressive regimens. Methods. We studied retrospectively 473 patients who received deceased donor kidney transplants with at least 1 allograft biopsy between January 1990 and May 2007. Clinical data included age, gender, biopsy data, and immunosuppression before and after kidney biopsy. Mean age was 45.4 +/- 12.7 years including 65% males with a mean follow-up of 6.7 +/- 4.5 years. CAD was observed in 177 of 473 biopsies: 48 patients showed interstitial fibrosis (IF); 101 chronic rejection (CR); 16 transplant glomerulopathy (TG); and 12, CR and TG. Mean follow-up since the discovery of the histologic feature was 60.5 +/- 50.5 months for IF; 38.3 +/- 40.8 for CR, and 1.8.2 +/- 19.2 for TG. Results. CAD, which was more common in younger patients (P =.03), correlated upon univariate and multivariate analysis with CKD stage 5d development (P <.001). Deposition of C4d in peritubular capillaries was more frequent among CAD patients (P =.004), an association with particular relevance to recipients with CR (P =.02) and TG (P <.001). When we analyzed CAD subpopulation, we observed a positive correlation between allograft survival and immunosuppression modification after biopsy. Substitution of sirolimus (40/177) was shown in univariate, multivariate and Cox regression analyses to be a renal protector (P <.002). Allograft survival was also correlated with initial mycophenolate mofetil versus azathioprine, (62/177) immunosuppression (P <.001). Conclusion. CAD, a frequent histologic feature, may benefit from sirolimus conversion.
Original languageUnknown
Pages (from-to)874-876
JournalTransplantation Proceedings
Issue number3
Publication statusPublished - 1 Jan 2009

Cite this